Table 4. Lab investigations of patients in two treatment groups.
| Parameters | Control group (n = 26) | Change in control group | Liraglutide group (n = 26) | Change in liraglutide group | p value | ||
|---|---|---|---|---|---|---|---|
| Before treatment | 7 days later | Before treatment | 7 days later | ||||
| Fasting blood glucose (mmol/L) | 8.5 ± 3.2 | 6.4 ± 1.5 | –2.3 (–3.5 to –1.5) | 8.6 ± 3.8 | 5.2 ± 1.8 | –3.5 (–5.5 to –1.8)* | 0.01 |
| Total cholesterol (mg/dL) | 169.8 ± 25.6 | 151.8 ± 22.6 | 18.9 (–28.4 to –9.5) | 175.3 ± 34.5 | 152.7 ± 23.8 | –22.8 (–32.7 to –9.4) | 0.17 |
| Triglyceride (mg/dL) | 92.2 ± 10.6 | 84.5 ± 10.8 | –8.4 (–13.6 to –3.5) | 92.8 ± 12.8 | 82.8 ± 9.5 | –9.5 (–15.6 to –5.5) | 0.43 |
| LDL cholesterol (mg/dL) | 94.8 ± 22.7 | 82.7 ± 17.8 | –12.2 (–21.4 to –3.5) | 95.1 ± 22.8 | 77.3 ± 18.4 | –17.8 (–27.2 to –7.5) | 0.29 |
| NT–pro-BNP (pg/ml) | 871.5 ± 338.6 | 216.8 ± 96.1 | –645.9 (–871.4 to –412.6) | 846.1 ± 384.6 | 95.5 ± 36.8 | –751.6 (–1061.2 to –465.5) | < 0.001 |
| hsCRP (mg/dL) | 1.08 ± 0.48 | 0.92 ± 0.38 | –0.18 (–0.25 to –0.08) | 1.06 ± 0.45 | 0.72 ± 0.35 | –0.35 (–0.48 to –0.19)* | < 0.001 |
| Interleukin-6 (pg/mL) | 14.7 ± 3.2 | 8.4 ± 2.5 | –6.8 (–9.5 to –3.4) | 15.2 ± 3.8 | 7.4 ± 2.5 | –7.9 (–11.4 to –3.2) | 0.27 |
| SOD (U/mL) | 105.7 ± 22.8 | 112.7 ± 21.5 | +6.5 (+2.8 to +9.4) | 102.8 ± 21.4 | 124.5 ± 20.6 | +20.7 (+9.5 to +32.8)* | < 0.001 |
| Malondialdehyde (nmol/mL) | 6.08 ± 1.84 | 6.02 ± 1.55 | –0.06 (–0.09 to –0.02) | 6.07 ± 1.93 | 5.92 ± 1.77 | –0.15 (–0.23 to –0.07)* | < 0.001 |
| NO (umol/L) | 51.7 ± 8.4 | 59.4 ± 9.3 | +8.3 (+3.5 to +12.8) | 52.1 ± 8.5 | 61.2 ± 9.2 | +9.5 (+5.2 to +13.4) | 0.28 |
| NOS (U/mL) | 8.84 ± 0.14 | 9.85 ± 0.13 | +0.98 (+0.52 to +1.38) | 8.95 ± 0.12 | 10.2 ± 0.18 | +1.11 (+0.52 to +1.63) | 0.31 |
Values represent the mean ± standard deviation. *P < 0.05 liraglutide group vs. control group by 2-way ANOVA. LDL, low- density lipoprotein; hsCRP, high-sensitivity C-reactive protein; SOD, superoxide dismutase; NO, nitric oxide; NOS, nitric oxide synthase; NT-pro-BNP, N-terminal pro-brain natriuretic peptide.